The curious relationship between one of the world’s biggest drug makers and President Trump’s personal lawyer began early last year when Michael Cohen, a longtime fixer for the president, reached out to Novartis’s then-chief executive officer Joe Jimenez, promising help gaining access to Trump and influential officials in the new administration, according to an employee inside Novartis familiar with the matter.
Jimenez took the call and then instructed his team to reach a deal with Cohen. A one-year contract worth $1.2 million was signed with Cohen in February 2017. The company’s hope was that Cohen could help it navigate a bevy of uncertain issues facing the drug maker — from potential changes to the Affordable Care Act and tax reform to navigating reimbursement challenges for medicines.
“He reached out to us,” the Novartis employee said, providing STAT with the company’s version of events as it scrambles to contain the fallout from being entangled in the investigations surrounding Trump and his inner circle, including Cohen. “With a new administration coming in, basically, all the traditional contacts disappeared and they were all new players. We were trying to find an inroad into the administration. Cohen promised access to not just Trump, but also the circle around him. It was almost as if we were hiring him as a lobbyist.”
The employee could not explain why Novartis would have agreed to a deal with a lawyer with no background in health care and without deep Washington ties. The extent to which Novartis conducted any due diligence into Cohen or his track record as a Trump insider and Washington player is uncertain. Cohen and Jimenez could not be reached for comment.
In March 2017, a group of Novartis employees, mostly from the government affairs and lobbying teams, met with Cohen in New York to discuss specific issues and strategies. But the meeting was a disappointment, the insider explained, and the Novartis squad left with the impression that Cohen and Essential Consultants — the firm controlled by Cohen that Novartis was making payments to — may not be able to deliver.
“At first, it all sounded impressive, but toward the end of the meeting, everyone realized this was a probably a slippery slope to engage him. So they decided not to really engage Cohen for any activities after that,” the employee continued. Rather than attempt to cancel the contract, the company allowed it to lapse early in 2018 and not run the risk of ticking off the president. “It might have caused anger,” this person said.
As the contract expiration date neared earlier this year, Cohen then approached Vasant Narasimhan, who by then had succeeded Jimenez as Novartis chief executive, according to the employee. Narasimhan declined to renew the arrangement and the contract lapsed.
A Novartis spokesman on Wednesday maintained that Narasimhan had no involvement with the contract. “This episode was clearly a mistake,” the spokesman said.